AZEVONE ORO (CALCIUM OROTATE(740MG), VITAMIN D3(1000 IU) & MAGNESIUM OXIDE(10MG) TABLET)

AZEVONE ORO Tablet is categorized under ‘Vitamins’ and is primarily utilized for addressing nutritional deficiencies. This medication is effective in managing conditions arising from inadequate calcium levels in the body, such as Vitamin D deficiency. Nutritional deficiency can occur when the body fails to absorb enough nutrients or when the intake from food is insufficient. This situation may lead to various health complications, including abnormal bone development, skin issues, digestive problems, and cognitive decline, like memory loss. The formulation of AZEVONE ORO Tablet includes elemental calcium and Vitamin D3 (Cholecalciferol). Elemental calcium is a vital mineral critical for preventing and treating calcium deficiencies, as it supplies necessary nutrients to support bone structure and health. Vitamin D3, a steroid hormone, is synthesized in the skin upon exposure to sunlight or can be acquired through dietary sources. It plays a key role in regulating blood calcium and phosphorus levels and is essential for proper bone mineralization. It is important to adhere to your healthcare provider’s instructions when taking AZEVONE ORO Tablet. The medication is generally considered safe; however, some individuals may experience mild side effects such as constipation and stomach discomfort which are typically not serious and tend to resolve on their own. It is important to avoid this medication if you have a known allergy to any of its components. Additionally, individuals with conditions such as hypercalcemia, hypervitaminosis D, malabsorption syndromes, low bile production, or phosphate imbalances should inform their healthcare provider before initiating treatment. Pregnant or nursing women should seek medical advice prior to using this tablet. Individuals with a history of kidney issues or elevated Vitamin D levels should refrain from taking AZEVONE ORO Tablet. It is deemed safe for pediatric use only under medical guidance.